English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/3244
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorPérez Jiménez, Eva-
dc.contributor.authorLarraga, Vicente-
dc.contributor.authorEsteban, Mariano-
dc.date.accessioned2008-03-18T12:49:07Z-
dc.date.available2008-03-18T12:49:07Z-
dc.date.issued2007-02-08-
dc.identifier.citationInternational Publication Number: WO 2007/014977 A1en_US
dc.identifier.urihttp://hdl.handle.net/10261/3244-
dc.descriptionFiling Date: 2006-07-28. --Priority Data: ES P200501886 (2005-07-30)en_US
dc.description.abstract[EN]The invention relates to recombinant vectors based on the Modified Vaccinia Ankara (MVA) virus as vaccines against leishmaniasis. The inventive vectors contain sequences encoding the LACK protein, which are preferably inserted into the hemagglutinin locus of the virus under the control of a promoter which enables the expression of same throughout the infection cycle of the virus. The invention comprises stable, safe vectors which elicit a strong immune response that provides protection against leishmaniasis and which, as such, are particularly suitable for use in vaccination against said disease, especially in humans, as well as in the largest animal reservoir of said anthropozoonosis, i.e. dogs.en_US
dc.description.abstract[ES]Vectores recombinantes basados en el virus vaccinia modificado de Ankara (MVA) como vacunas contra la leishmaniasis. Los vectores de la invención contienen secuencias codificantes de la proteína LACK, preferentemente insertadas en el locus de hemaglutinina del virus y bajo el control de un promotor que permite su expresión a lo largo del ciclo de infección del virus. Son vectores seguros, estables, que dan lugar a una potente respuesta inmune que confiere protección frente a la leishmaniasis, por lo que son buenos candidatos para ser utilizados en vacunación frente a esta enfermedad, especialmente en seres humanos, así como en el reservorio animal más importante de esta antropozoonosis, los perros-
dc.format.extent4872679 bytes-
dc.format.mimetypeapplication/pdf-
dc.language.isoengen_US
dc.rightsopenAccessen_US
dc.titleRecombinant vectors based on the Modified Vaccinia Ankara (MVA) virus as vaccines against leishmaniasisen_US
dc.titleVectores recombinantes basados en el virus vaccinia modificado de Ankara (MVA) como vacunas contra la leishmaniasis-
dc.typepatenteen_US
dc.description.peerreviewedPeer revieweden_US
Appears in Collections:(CIB) Patentes
(CNB) Patentes
Files in This Item:
File Description SizeFormat 
WO_2007_014977_A1[1].pdf4,76 MBAdobe PDFThumbnail
View/Open
Show simple item record
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.